CDTX

Cidara Therapeutics, Inc. (CDTX) | Rumor.io

Cidara Therapeutics

CDTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)99%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CDTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Jan 7

Merck (MRK) has completed its acquisition of Cidara Therapeutics (CDTX) at $221.50 per share, with CDTX delisting and becoming a wholly owned subsidiary.
The acquisition is expected to strengthen Merck's infectious disease portfolio and expand its reach in seasonal and pandemic markets.
The deal is valued at approximately $9.2 billion and is booked as a research and development (R&D) hit in 2026, with CDTX's long-acting flu-prevention antiviral, CD388, now in Phase 3.

Generated by AI

Sentiment

Of the messages about CDTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +18.18	93.35% +9.26
Bearish	0%	0%	0% -18.18	6.65% -9.26

Bullish· Nov 14

Cidara Therapeutics, Inc. (CDTX) has seen a significant increase in value, with a buyout offer from Merck at $221.50 per share.
The company's valuation has risen by over 9000% from $100 million to $9.2 billion, demonstrating the potential for long-term growth in the biotech industry.
The acquisition by Merck could be a game-changer for the company, with the potential to move the needle for the pharmaceutical giant.

Bearish· Nov 14

$CDTX's acquisition by Merck for $221.50/share in cash represents a steep premium, with the stock trading at $201.40 premarket.
The deal may have been avoidable, as JNJ passed on acquiring CDTX in 2023, potentially due to the company's high valuation.
The acquisition price may be unsustainable, with some users predicting that the stock will drop to its true worth.

Generated by AI

Topics

Of the messages about CDTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	85.97%
Analysts	0%	0%	0%	5.64%
Controversies	0%	0%	0%	1.89%
Earnings	0%	0%	0%	1.19%
Macro	0%	0%	0%	0.8%
Technical Analysis	0%	0%	0%	4.51%

Earnings· Feb 27

Cidara Therapeutics, Inc. ($CDTX) beat EPS loss estimates by $0.15.
Since the last earnings report, $CDTX stock dropped 17%.
$CDTX reported a loss of $0.69, beating the consensus estimate of ($0.73).

Announcements· Nov 14

Merck ($MRK) is acquiring Cidara Therapeutics ($CDTX) for $221.50 per share in cash, valuing the deal at approximately $9.2 billion.
The acquisition is primarily for Merck's long-acting flu prevention drug candidate, CD388, which has FDA Breakthrough Therapy status and is currently in a 6,000-patient Phase 3 study.
Cidara Therapeutics shareholders are expected to see significant returns, with the company's valuation increasing by over 1,700% since its reverse split in April last year.

Technical Analysis· Apr 5

$CDTX is looking to close the gap from the open and a better entry point is now available.
The stock is expected to bounce at support levels around $2.80 or $2.77.
Closing the gap at $2.68 is seen as a positive development for the stock's upside potential.

Generated by AI

Community

Of the messages about CDTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	88.89%	97.33%	60.9%
Newcomers	100%	11.11%	2.67%	39.1%

Regulars· Nov 14

Merck has acquired Cidara Therapeutics (CDTX) for $221.50 per share in an all-cash deal worth approximately $9.2 billion.
Regular investors are celebrating the significant returns on their investment, with one owner reporting a 1500% gain since buying shares at $0.38.
The acquisition price of $221.50 per share represents a significant premium over the stock's price, with one investor noting that the actual bid was an "INCREDIBLE premium" for CDTX.

Newcomers· Nov 14

Many newcomers are drawn to $CDTX due to its 288% YTD gain, making it an impressive example of exit engineering.
The $CDTX acquisition by Merck for $221.50 per share in cash, valuing the deal at approximately $9.2 billion, is seen as a great case study of longevity and reinvention in biotech.
Newcomers are impressed by the speed and magnitude of the gain, with one user noting that a $1000 investment yesterday would have turned into $1,000,000 today.

Generated by AI

Also Discussed

Investors talking about CDTX also mention

#	Name	Attention
1	Ardelyx IncARDX	0.01%+0.01
2	SCYNEXIS, Inc. Common StockSCYX	0%-0.02
3	PRTK - Paratek Pharmaceuticals, Inc.	——
4	ETNB - 89bio, Inc.	——
5	Seres Therapeutics Inc.MCRB	0%0
6	Abivax SAABVX	0.01%-0.01
7	SWTX - SpringWorks Therapeutics, Inc.	——
8	CytomX Therapeutics, Inc.CTMX	0%0
9	Apogee Therapeutics, Inc. - Common StockAPGE	0%0
10	CGBS - Crown LNG Holdings Limited	——